GlassScriptPhysician profile
Marie Blankenship
NPI 1497050645
$5,845.30
in general payments reported to CMS, 2019-2025
67 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,154 · 2022: $922 · 2023: $628 · 2024: $1,230 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Education: $199 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.00 |
| Education | $198.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,059.58 | 2021-2025 | |
| Pfizer INC. | $349.67 | 2022-2025 | |
| Daiichi Sankyo INC. | $348.60 | 2021-2025 | Enhertu, Injectafer |
| Celgene Corporation | $284.64 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $232.50 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $230.02 | 2021-2025 | Enhertu, Tagrisso |
| Gilead Sciences, INC. | $219.54 | 2023-2025 | Trodelvy, Epclusa |
| Abbvie INC. | $205.80 | 2022-2025 | |
| Genentech USA, INC. | $173.55 | 2022-2023 | Tecentriq, Phesgo |
| Bayer Healthcare Pharmaceuticals INC. | $145.25 | 2022-2025 | |
| Amgen INC. | $141.00 | 2023-2025 | Otezla, Otezla |
| Axsome Therapeutics, INC. | $115.99 | 2025 | Auvelity |
| Radius Health, INC. | $115.37 | 2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $114.60 | 2025 | Voquezna |
| Incyte Corporation | $113.72 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Blankenship listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.